Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for inflammation control after traumatic brain injury
ISRCTN16877626Phase 2Recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of tocilizumab in traumatic brain injury (TBI) (4 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Mar 2026; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on ISRCTN16877626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16877626.